Avacta Group PLC AVCT
Trading Information
- Previous Close Price
- GBX72.50
- Day Range
- GBX71.00–74.00
- 52-Week Range
- GBX48.00–92.00
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 468.55M
- Market Cap
- GBX33.74B
- Volume/Avg
- 614,155 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,769.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://avacta.com
Valuation
|
Metric
|
AVCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 89.51 |
Price/Sales | 2,769.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVCT
|
|---|---|
Quick Ratio | 0.95 |
Current Ratio | 0.95 |
Interest Coverage | −4.86 |
Quick Ratio
AVCT
Profitability
|
Metric
|
AVCT
|
|---|---|
Return on Assets (Normalized) | −112.85% |
Return on Equity (Normalized) | −1,601.77% |
Return on Invested Capital (Normalized) | −150.39% |
Return on Assets
AVCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Y&%dYX! | LOCK|FCCD | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!#<bpL$ | LOCK|w>#yK | $76B | |||
| Moderna Inc
MRNA
| LOCK|K@&$%b | LOCK|!@ | $75B | |||
| argenx SE ADR
ARGX
| LOCK|vl$zBx | LOCK|kk | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|D@!<<m% | LOCK|VZ# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$#f^b^ | LOCK|?r@yN | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|WNx@<$!w | LOCK|&z$!q | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|B&yBdS | LOCK|&# | $24B | |||
| Incyte Corp
INCY
| LOCK|b<h$<F | LOCK|z! | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|bWS%?! | LOCK|Z!# | $15B |
United States